Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week
Epistemonikos ID: d453fd8896f48d5d3992a93ce4371739bc85ade3
First added on: May 15, 2024